论文部分内容阅读
目的探讨多巴胺、多巴酚丁胺、氨溴索联合佐治小儿重症肺部感染疗效及对免疫、炎性因子水平影响,为临床治疗提供依据。方法选取2014年1月-2015年12月医院收治小儿重症肺部感染患儿100例,分为2组,对照组44例在常规治疗基础上给予多巴胺、多巴酚丁胺治疗,观察组56例在对照组基础上给予氨溴索治疗;于治疗前、治疗后3、10d抽取空腹肘静脉血5ml送检,观察炎性因子白介素-6(IL-6)、白介素-8(IL-8)、C反应蛋白(CRP)、肿瘤坏死因子ɑ(TNF-α),及免疫因子CD_3~+、CD_4~+、CD_8~+变化,于治疗10d后评定治疗效果及不良反应。结果经10d治疗,观察组总有效率98.21%高于对照组(P<0.05);观察组治疗3、10d各项炎性因子均低于同组治疗前及对照组同期(P<0.05);观察组治疗3、10d各项免疫因子均高于同组治疗前及对照组同期(P<0.05)。结论多巴胺、多巴酚丁胺、氨溴索联合佐治小儿重症肺部感染可降低机体炎性因子水平,改善免疫功能,治疗效果满意,值得临床推广。
Objective To investigate the effects of dopamine, dobutamine and ambroxol combined with adjuvant chemotherapy on children with severe pulmonary infection and their effects on the immune and inflammatory cytokines and provide the basis for clinical treatment. Methods From January 2014 to December 2015, 100 children with severe pulmonary infection were admitted to our hospital from January 2014 to December 2015. The patients were divided into two groups. The control group received routine dopamine and dobutamine treatment. The observation group 56 Patients were treated with ambroxol on the basis of the control group. Before treatment, 5 ml of fasting elbow venous blood was collected on the 3rd and 10th day after the treatment, and the levels of interleukin-6 (IL-6), interleukin-8 CRP, TNF-α, CD_3 ~ +, CD_4 ~ + and CD_8 ~ + were measured. The therapeutic effects and adverse reactions were evaluated after 10 days of treatment. Results The total effective rate in the observation group was 98.21% (P <0.05) after 10 days of treatment. The inflammatory factors in the observation group at 3 and 10 days were lower than those in the same group before treatment and the control group (P <0.05). The immune factors in the observation group at 3 and 10 days were higher than those in the same group before treatment and in the control group (P <0.05). Conclusions Dopamine, dobutamine and ambroxol combined with adjuvant treatment of pediatric severe pulmonary infection can reduce the levels of inflammatory cytokines in the body and improve the immune function. The treatment effect is satisfactory and worthy of clinical promotion.